Recently, HEC Pharmaceutical's independently developed Class 1 innovative drug...Ologagliptin capsules have been approved for marketing by the National Medical Products Administration for use as monotherapy or in combination with metformin to improve glycemic control in adult patients with type 2 diabetes. As a new member of the domestic SGLT-2 drug market, its approval is a significant achievement for HEC.This is a milestone in R&D capabilities and a significant breakthrough for the company in the field of innovative drugs .

According to the latest report released by the International Diabetes Federation (IDF), there are approximately 150 million adults with diabetes in China, of whom over 90% have type 2 diabetes. Although oral hypoglycemic agents have achieved multi-mechanism coverage, significant clinical challenges remain: on the one hand, patient adherence to medication is generally poor, with an effective blood glucose control rate of only 50.1%; on the other hand, diabetes is often accompanied by complications such as obesity, hypertension, and heart and kidney damage, making simple blood glucose control insufficient to meet the needs of comprehensive management throughout the entire lifecycle of blood glucose, metabolism, and organ protection.

Among the many mechanisms of blood sugar control, SGLT-2 inhibitors have become a first-line clinical choice since entering the Chinese market due to their insulin-independent blood sugar-lowering pathway and multiple benefits in weight loss, blood pressure reduction, and cardio- and renal protection. Based on currently available clinical data, this drug exhibits some noteworthy differentiated characteristics compared to other SGLT-2 inhibitors, including core blood sugar-lowering indicators and the balance of overall metabolic benefits. Ologagliptin also demonstrates robust safety profiles.

Currently, HEC Pharmaceutical has built a well-defined and mutually supportive array of metabolic products, developing products based on needs such as oral administration, long-acting, and multi-target combination therapy. It has expanded outward from the core area of diabetes to cover metabolic diseases such as obesity and metabolic-associated steatohepatitis (MASH), including 5 insulins, the SGLT-2 inhibitor oligogliflozin, GLP-1 multi-target agonists, and innovative therapies such as small nucleic acid technology.

A representative from HEC Pharmaceutical stated that the approval of oligogliflozin is a significant step forward for the company in its long-term chronic disease management strategy. The company will continue to systematically advance its iterative and innovative product development, providing high-quality solutions for patients with diabetes and cardiovascular metabolic diseases, from precision treatment to full-cycle management.

https://finance.eastmoney.com/a/202601163622173617.html